MedTrace Logo

Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls

NCT03649555 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-09-10

No results posted yet for this study

Summary

The purpose of this study is to understand the reliability of \[18F\]-FTC-146 brain uptake in healthy controls.

Conditions

  • Healthy Controls

Interventions

DRUG

[18F]-FTC-146

Two 5 mCi \[18F\]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.

Sponsors & Collaborators

Principal Investigators

  • Carolyn Rodriguez, MD, PhD · Stanford University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-03-03
Completion
2021-03-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649555 on ClinicalTrials.gov